FDA panel backs filgrastim as nuke attack countermeasure
This article was originally published in Scrip
Executive Summary
A panel of outside expert advisers to the US FDA on 3 May voted 17-1 that treatment with Amgen's Neupogen (filgrastim) would reasonably be likely to produce clinical benefits in humans exposed to radiation likely to induce myelosupppression during or following a radiological or nuclear incident.